کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5656731 | 1407375 | 2016 | 4 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Ãzétimibe : plus de preuves pour un effet sur la réduction du risque cardiovasculaire
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
غدد درون ریز، دیابت و متابولیسم
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Ezetimibe is an agent reducing intestinal cholesterol absorption by inhibiting NPC1L1 transporter. This reduction in cholesterol absorption induces, via a decrease in the cholesterol pool in the hepatocytes, an increase in LDL receptor expression leading to enhance LDL-cholesterol (LDLc) catabolism and, as a consequence, to reduce plasma LDLc level. Recently, came out important pieces of evidence for the efficiency of ezetimibe to reduce cardiovascular risk. A large Genome Wide Association Study showed that individuals with inactivating mutations of NPC1L1 had, in parallel with a decreased LDLc plasma level, a significant reduced cardiovascular risk. The PRECISE-IVUS study demonstrated a higher rate of coronary atherosclerotic plaque regression in patients treated with atorvastatin + ezetimibe compared to those treated with atorvastatin alone. In addition, the prospective IMPROVE-IT trial, had shown a significant reduction in major cardiovascular events (P=0.016), in myocardial infarction (P=0.002), in ischemic stroke (P=0.008), in coronary mortality (P=0.02), and in cardiovascular mortality (P=0.04) in patients treated with simvastatin + ezetimibe compared to those treated with simvastatin alone.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Médecine des Maladies Métaboliques - Volume 10, Issue 5, September 2016, Pages 430-433
Journal: Médecine des Maladies Métaboliques - Volume 10, Issue 5, September 2016, Pages 430-433
نویسندگان
B. Vergès,